Skip to main content
Zai Lab Limited logo

Zai Lab Limited — Investor Relations & Filings

Ticker · 9688 ISIN · KYG9887T1168 LEI · 549300P2UYQ9U5LY1T58 HKEX Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2026-05-22 Board/Management Inform…
Country KY Cayman Islands
Listing HKEX 9688

About Zai Lab Limited

http://www.zailaboratory.com

Zai Lab Limited is an innovative, research-based, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing transformative therapies that address medical conditions with significant unmet needs. The company focuses its pipeline and development efforts across four core therapeutic areas: oncology, immunology, neuroscience, and infectious disease. Zai Lab employs a strategy of internal research and global partnerships to advance best-in-class and first-in-class medicines. A key commercial product is ZEJULA (niraparib), utilized as a maintenance treatment for ovarian cancer in markets including mainland China.

Recent filings

Filing Released Lang Actions
OVERSEAS REGULATORY ANNOUNCEMENT - FORM 8-K
Board/Management Information Classification · 91% confidence The document is an Overseas Regulatory Announcement of a Form 8-K filed with the U.S. SEC, specifically Item 5.02 regarding the departure of the President and COO and reassignment of his duties. This is an announcement of changes in senior management, matching the definition for Board/Management Information (MANG).
2026-05-22 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS
Share Issue/Capital Change Classification · 84% confidence The document is a Listing Rules announcement disclosing the grant of share options and restricted share units under the company’s equity incentive plan. It is not an earnings release, management discussion, or AGM material but a notification of a capital change (share‐based awards). Under our taxonomy, this falls under “Share Issue/Capital Change” (SHA).
2026-05-12 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2026
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return filed with the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for Zai Lab Limited. It includes information on authorized and issued share capital, share options, equity incentive plans, and confirmations related to compliance with listing rules. The document is a regulatory submission about share capital movements and public float sufficiency, not a financial report, earnings release, or management discussion. It is not an announcement of a report publication but a substantive regulatory filing. The form code FF301 and the nature of the content indicate it is a regulatory filing related to share capital and securities movements under HKEX rules, which fits best under the category of Regulatory Filings (RNS).
2026-05-07 English
OVERSEAS REGULATORY ANNOUNCEMENT - FORM 10-Q
Interim / Quarterly Report Classification · 100% confidence The document is titled as an "OVERSEAS REGULATORY ANNOUNCEMENT - FORM 10-Q" and explicitly states that the company filed a Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. The text includes detailed financial statements, management discussion and analysis, risk factors, and other typical contents of a quarterly report. The document length is substantial (15,000 characters), indicating it contains the full report rather than just an announcement or a link to the report. The presence of unaudited financial statements and the SEC Form 10-Q designation confirms this is a quarterly financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-07 English
UNAUDITED RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND CORPORATE UPDATES
Interim / Quarterly Report Classification · 100% confidence The document is an announcement of unaudited financial results for the three months ended March 31, 2026, which corresponds to a quarterly period. It includes detailed financial data such as revenues, expenses, net loss, and cash position, as well as extensive corporate updates and pipeline highlights. The document also mentions a conference call and webcast for discussing these results. The presence of actual financial statements and substantive financial data for a quarter indicates this is an Interim / Quarterly Report. The document is about 15,000 characters long, which is consistent with a full report rather than a brief announcement or a certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2026
2026-05-07 English
2025 ESG REPORT
Environmental & Social Information Classification · 92% confidence The document is titled “Trust for Life Report,” covers corporate sustainability metrics, ESG commitments (UN SDGs, SASB index, HKEx disclosures), and focuses on environmental, social, and governance performance rather than financial results. It is a standalone sustainability/ESG report, fitting the Environmental & Social Information category.
2026-04-28 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.